Trevi Therapeutics Inc TRVI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TRVI is a good fit for your portfolio.
News
-
Trevi Therapeutics Announces Abstract Presentation at the American Thoracic Society 2024 International Conference
-
Trevi Therapeutics to Participate in Upcoming April Events
-
Trevi Therapeutics Adds Clinical Development Expertise in Chronic Cough to Leadership Team
-
Trevi Therapeutics Reports Fourth Quarter and Year End 2023 Financial Results and Provides Business Updates
-
Trevi Therapeutics to Report Q4 and Year End 2023 Financial Results and Provide a Corporate Update on March 20, 2024
-
Trevi Therapeutics to Participate in Upcoming March Events
-
Trevi Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Trading Information
- Previous Close Price
- $2.55
- Day Range
- $2.50–2.74
- 52-Week Range
- $0.98–4.00
- Bid/Ask
- $2.72 / $2.79
- Market Cap
- $188.95 Mil
- Volume/Avg
- 21,019 / 314,967
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 25
Comparables
Valuation
|
Metric
|
TRVI
|
MDGL
|
CBAY
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 2.10 | 9.53 | 12.65 |
Price/Sales | — | — | 111.01 |
Price/Cash Flow | — | — | — |
Price/Earnings
TRVI
MDGL
CBAY
Financial Strength
|
Metric
|
TRVI
|
MDGL
|
CBAY
|
|---|---|---|---|
Quick Ratio | 14.25 | 5.35 | 10.70 |
Current Ratio | 15.03 | 5.38 | 10.96 |
Interest Coverage | −85.56 | −29.93 | −5.27 |
Quick Ratio
TRVI
MDGL
CBAY
Profitability
|
Metric
|
TRVI
|
MDGL
|
CBAY
|
|---|---|---|---|
Return on Assets (Normalized) | −25.14% | −86.33% | −30.06% |
Return on Equity (Normalized) | −27.73% | −184.32% | −51.97% |
Return on Invested Capital (Normalized) | −30.85% | −122.82% | −30.87% |
Return on Assets
TRVI
MDGL
CBAY
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Vlffsgdjk | Vkq | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Yfsyvpr | Svgyqx | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Mdcygnwq | Ssbltr | $97.8 Bil | |
MRNA
| Moderna Inc | Zvypwbtwd | Nfmsh | $38.8 Bil | |
ARGX
| argenx SE ADR | Wdddkhccc | Jtdnh | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Dpnzlrzb | Sjkzm | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Ntfsjlbx | Gftsc | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Mlbwcxwh | Swnzddg | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hnnlfjnrzf | Zwgcbv | $12.5 Bil | |
INCY
| Incyte Corp | Nfsmlfyhf | Vvlchd | $11.5 Bil |